Targeting key proximal drivers of type 2 inflammation in disease
The DOI matches its Crossref record; 154 of the 156 references it cites were found in a registry or an index.
Abstract
Systemic type 2 inflammation encompassing T helper 2 (TH2)-type responses is emerging as a unifying feature of both classically defined allergic diseases, such as asthma, and a range of other inflammatory diseases. Rather than reducing inflammation with broad-acting immunosuppressants or narrowly targeting downstream products of the TH2 pathway, such as immunoglobulin E (IgE), efforts to target the key proximal type 2 cytokines - interleukin-4 (IL-4), IL-5 and IL-13 - represent a promising strategy to achieve therapeutic benefit across multiple diseases. After several initial disappointing clinical results with therapies targeting IL-4, IL-5 or IL-13 in asthma, applying a personalized approach achieved therapeutic benefit in an asthma subtype exhibiting an 'allergic' phenotype. More recently, efficacy was extended into a broad population of people with asthma. This argues that the Type 2 inflammation is broadly relevant across the severe asthma population if the key upstream drivers are properly blocked. Moreover, the simultaneous inhibition of IL-4 and IL-13 has shown significant clinical activity in diseases that are often co-morbid with asthma - atopic dermatitis and chronic sinusitis with nasal polyps - supporting the hypothesis that targeting a central 'driver pathway' could benefit multiple allergic diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lebrikizumab does not affect the binding of IL-13 to the IL-13Rα2 receptor chain, the biological role of which remains unclear81.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [81]
Citations
Cites
GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION
PAUWELS, R. A. (1996) · Arerugī/Arerugi · doi:10.15036/arerugi.45.792 · Cited by 9,994
Williams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,599
Asher, M. I., Montefort, S., Björkstén, B., Lai, C. K., Strachan, D. P., Weiland, S. K., & Williams, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69283-0 · Cited by 4,223
Interleukin-13: Central Mediator of Allergic Asthma
Wills-Karp, M., Luyimbazi, J., Xu, X., Schofield, B., Neben, T. Y., Karp, C. L., & Donaldson, D. D. (1998) · Science · doi:10.1126/science.282.5397.2258 · Cited by 2,617
Development and validation of a questionnaire to measure asthma control
Juniper, E. F., O′byrne, P. M., Guyatt, G. H., Ferrie, P. J., & King, D. R. (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.14d29.x · Cited by 2,473
Fokkens, W. J., Lund, V. J., Mullol, J., Bachert, C., Alobid, I., Baroody, F., Cohen, N., Cervin, A., Douglas, R., Gevaert, P., et al. (2012) · Rhinology journal · doi:10.4193/rhino12.000 · Cited by 2,387
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., Humbert, M., Katz, L. E., Keene, O. N., Yancey, S. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403290 · Cited by 2,322
Severity Scoring of Atopic Dermatitis: The SCORAD Index
(2009) · Dermatology · doi:10.1159/000247298 · Cited by 2,273
Pavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program
Moore, W. C., Meyers, D. A., Wenzel, S. E., Teague, W. G., Li, H., Li, X., D'Agostino, R., Castro, M., Curran-Everett, D., Fitzpatrick, A. M., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0896oc · Cited by 2,129
Research works printed but not linked: 5
- Pawankar, R., Canonica, G., Holgate, S. & Lockey, R. WAO White Book on Allergy 2011–2012: Executive Summary (World Allergy Organization, 2011).
- Wenzel, S. E. et al. Inhaled pitrakinra, an IL-4/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma. Eur. Respir. J. 36 (Suppl. 54), 713s (2010).
- Wenzel, S. et al. Dupilumab improves lung function and reduces severe exacerbations in uncontrolled asthmatics with baseline eosinophil levels above and below 300 cells/μl. Am. J. Respir. Crit. Care Med. 191, A3632 (2015).
- Kaiser, J. Medical Officer's Efficacy Review, Genentech, Omalizumab BLA STN 103976/0. US Food and Drug Administration [online] , (2003).
- Groves, R., Wilbrahams, D., Fuller, R. & Longphre, M. Inhibition of IL-4 and IL-13 with an IL-4 mutein (Aeroderm) protects against flares in atopic eczema. J. Invest. Dermatol. 127 (Suppl. 1s), S54 (2007).
Cited by
Items 101–200 of 800
The emerging role of type 2 inflammation in asthma
Matucci, A., Bormioli, S., Nencini, F., Maggi, E., & Vultaggio, A. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1860755 · Cited by 74
Paller, A. S., Siegfried, E. C., Simpson, E. L., Cork, M. J., Sidbury, R., Chen, I. H., Khokhar, F. A., Xiao, J., Dubost-Brama, A., & Bansal, A. (2024) · American Journal of Clinical Dermatology · doi:10.1007/s40257-024-00859-y · Cited by 77
Doroudchi, A., Pathria, M., & Modena, B. D. (2019) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2019.10.016 · Cited by 73
Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021
Saeki, H., Ohya, Y., Furuta, J., Arakawa, H., Ichiyama, S., Katsunuma, T., Katoh, N., Tanaka, A., Tsunemi, Y., Nakahara, T., et al. (2022) · Allergology International · doi:10.1016/j.alit.2022.06.009 · Cited by 69
Type 2 Inflammation and Asthma in Children: A Narrative Review
Papadopoulos, N. G., Bacharier, L. B., Jackson, D. J., Deschildre, A., Phipatanakul, W., Szefler, S. J., Gall, R., Ledanois, O., Jacob-Nara, J. A., & Sacks, H. J. (2024) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2024.06.010 · Cited by 74
Impact of Air Pollution on Atopic Dermatitis: A Comprehensive Review
Pan, Z., Dai, Y., Akar-Ghibril, N., Simpson, J., Ren, H., Zhang, L., Hou, Y., Wen, X., Chang, C. C.-C., Tang, R., et al. (2023) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-022-08957-7 · Cited by 73
Dupilumab for the treatment of asthma
Santini, G., Mores, N., Malerba, M., Mondino, C., Anzivino, R., Macis, G., & Montuschi, P. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1282458 · Cited by 64
Tsianakas, A., Luger, T. A., & Radin, A. R. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15905 · Cited by 66
English Version of Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021
Saeki, H., Ohya, Y., Furuta, J., Arakawa, H., Ichiyama, S., Katsunuma, T., Katoh, N., Tanaka, A., Tsunemi, Y., Nakahara, T., et al. (2022) · The Journal of Dermatology · doi:10.1111/1346-8138.16527 · Cited by 75
The effects of obesity on asthma: immunometabolic links
Miethe, S., Guarino, M., Alhamdan, F., Simon, H., Renz, H. E., Dufour, J., Potaczek, D. P., & Garn, H. (2018) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.4304 · Cited by 72
Song, Y., Wang, Z., Jiang, J., Piao, Y., Li, L., Xu, C., Piao, H., Li, L., & Yan, G. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15942 · Cited by 62
Real-world persistence with dupilumab among adults with atopic dermatitis
Silverberg, J. I., Guttman‐Yassky, E., Gadkari, A. S., Kuznik, A., Mallya, U. G., Mastey, V., Zhang, H., Chen, Z., Chen, C., Korotzer, A. R., et al. (2020) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2020.07.026 · Cited by 60
Asthma and Chronic Rhinosinusitis: How Similar Are They in Pathogenesis and Treatment Responses?
Matucci, A., Bormioli, S., Nencini, F., Chiccoli, F., Vivarelli, E., Maggi, E., & Vultaggio, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073340 · Cited by 62
Zhang, C., Chinnappan, M., Prestwood, C. A., Edwards, M., Artami, M., Thompson, B. M., Eckert, K. M., do Vale, G. D., Zouboulis, C. C., McDonald, J. G., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2100749118 · Cited by 64
Jang, D. H., Heo, S., Jung, H. J., Park, M. Y., Seo, S. J., & Ahn, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061982 · Cited by 58
Sonic Hedgehog signaling limits atopic dermatitis via Gli2-driven immune regulation
Papaioannou, E., Yánez, D. C., Ross, S. E., Lau, C., Solanki, A., Chawda, M. M., Virasami, A. K., Ranz, I., Lab), M. O. (., O’Shaughnessy, R. F. L., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125170 · Cited by 60
Pareek, A., Kumari, L., Pareek, A., Chaudhary, S., Ratan, Y., Janmeda, P., Chuturgoon, S., & Chuturgoon, A. A. (2024) · Cells · doi:10.3390/cells13050425 · Cited by 68
The Role of T Cells and Macrophages in Asthma Pathogenesis: A New Perspective on Mutual Crosstalk
Zhu, X., Cui, J., Yi, L., Qin, J., Wuniqiemu, T., Teng, F., Tang, W., Wei, Y., & Dong, J. (2020) · Mediators of Inflammation · doi:10.1155/2020/7835284 · Cited by 61
English version of clinical practice guidelines for the management of atopic dermatitis 2024
Saeki, H., Ohya, Y., Arakawa, H., Ichiyama, S., Katsunuma, T., Katoh, N., Tanaka, A., Tanizaki, H., Tsunemi, Y., Nakahara, T., et al. (2024) · The Journal of Dermatology · doi:10.1111/1346-8138.17544 · Cited by 59
Gelardi, M., Iannuzzi, L., Giosa, M. D., Taliente, S., Candia, N. D., Quaranta, N. A. A., Corso, E. D., Seccia, V., & Ciprandi, G. (2017) · Acta Otorhinolaryngologica Italica · doi:10.14639/0392-100x-1417 · Cited by 61
Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
Castro, M., Rabe, K. F., Corren, J., Pavord, I. D., Katelaris, C. H., Tohda, Y., Zhang, B., Rice, M. S., Maroni, J. M., Rowe, P., et al. (2020) · ERJ Open Research · doi:10.1183/23120541.00204-2019 · Cited by 57
Self-citationHan, D., Wang, F., Qiao, Z., Wang, B., Zhang, Y., Jiang, Q., Liu, M., Zhuang, Y., An, Q., Bai, Y., et al. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.11.016 · Cited by 65
Biologic Therapy for Atopic Dermatitis: Moving Beyond the Practice Parameter and Guidelines
Boguniewicz, M. (2017) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2017.08.031 · Cited by 55
Xiong, X., Zhu, M., Wu, H., Fan, L., & Cheng, D. (2019) · Respiratory Research · doi:10.1186/s12931-019-1065-3 · Cited by 56
The Role of Dupilumab in Severe Asthma
Ricciardolo, F. L. M., Bertolini, F., & Carriero, V. M. A. (2021) · Biomedicines · doi:10.3390/biomedicines9091096 · Cited by 57
Skin Immunosenescence and Type 2 Inflammation: A Mini-Review With an Inflammaging Perspective
Chen, B., Yang, J., Song, Y., Zhang, D., & Hao, F. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.835675 · Cited by 64
Treatment With Dupilumab in Patients With Atopic Dermatitis: Systematic Review and Meta-Analysis
Koskeridis, F., Εvangelou, Ε., Ntzani, E., Κostikas, Κ., & Tsabouri, S. (2022) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/12034754221130969 · Cited by 55
The hidden sentinel of the skin: An overview on the role of interleukin-13 in atopic dermatitis
Napolitano, M., di Vico, F., Ruggiero, A., Fabbrocini, G., & Patruno, C. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1165098 · Cited by 65
Dupilumab for the treatment of asthma
Pelaia, C., Vatrella, A., Gallelli, L., Terracciano, R., Navalesi, P., Maselli, R., & Pelaia, G. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1387245 · Cited by 53
Interactions of the immune and sensory nervous systems in atopy
Oetjen, L. K., & Kim, B. (2018) · FEBS Journal · doi:10.1111/febs.14465 · Cited by 55
Stapokibart (CM310) targets IL-4Rα for the treatment of type 2 inflammation
Liu, W., Zhao, Y., He, Y., Yan, X., Yu, J., Song, Q., Zhang, L., Dong, B., Xu, G., Wang, C., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110721 · Cited by 53
D’Auria, E., Panelli, S., Lunardon, L., Pajoro, M., Paradiso, L., Beretta, S., Loretelli, C., Tosi, D., Perini, M., Bedogni, G., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105284 · Cited by 58
Xie, L., Yang, K., Liang, Y., Zhu, Z., Yuan, Z., & Du, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.944801 · Cited by 53
Pathobiology of Type 2 Inflammation in Asthma and Nasal Polyposis
Pelaia, C., Pelaia, G., Maglio, A., Tinello, C., Gallelli, L., Lombardo, N., Terracciano, R., & Vatrella, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103371 · Cited by 45
Switching Biological Therapies in Severe Asthma
Scioscia, G., Nolasco, S., Campisi, R., Quarato, C. M. I., Caruso, C., Pelaia, C., Portacci, A., & Crimi, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119563 · Cited by 50
Molecular aspects of allergens in atopic dermatitis
Campana, R., Dzoro, S., Mittermann, I., Fedenko, E. S., Elisyutina, O. G., Khaitov, M. R., Karaulov, A. V., & Valenta, R. (2017) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000378 · Cited by 53
Pediatric obesity and severe asthma: Targeting pathways driving inflammation
Cicco, M. D., Ghezzi, M., Kantar, A., Song, W., Bush, A., Peroni, D. G., & D’Auria, E. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106658 · Cited by 52
Dupilumab‐induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis
Ryser, F. S., Yalamanoglu, A., Valaperti, A., Brühlmann, C., Mauthe, T., Traidl, S., Soyka, M., & Steiner, U. C. (2023) · Allergy · doi:10.1111/all.15844 · Cited by 48
Rather, I. A., Kim, B.-C., Lew, L.-C., Cha, S.-K., Lee, J. H., Nam, G.-J., Majumder, R., Lim, J., Lim, S.-K., Seo, Y., et al. (2020) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-020-09654-7 · Cited by 49
Immunopathology and Immunotherapy of Inflammatory Skin Diseases
Song, A., Lee, S. E., & Kim, J. H. (2022) · Immune Network · doi:10.4110/in.2022.22.e7 · Cited by 53
Targeting the T Helper 2 Inflammatory Axis in Atopic Dermatitis
Moreno, A. S., McPhee, R. A., Arruda, L. K., & Howell, M. D. (2016) · International Archives of Allergy and Immunology · doi:10.1159/000451083 · Cited by 49
GATA‐3‐specific DNAzyme — A novel approach for stratified asthma therapy
Garn, H., & Renz, H. (2016) · European Journal of Immunology · doi:10.1002/eji.201646450 · Cited by 51
Tomalin, L. E., Kim, J., Correa da Rosa, J., Lee, J., Fitz, L. J., Berstein, G., Valdez, H., Wolk, R., Krueger, J. G., & Suárez-Fariñas, M. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.09.023 · Cited by 46
New Topical Therapies in Development for Atopic Dermatitis
Freitas, E., Gooderham, M., & Torres, T. R. (2022) · Drugs · doi:10.1007/s40265-022-01722-2 · Cited by 47
Alobaidi, A. H., Alsamarai, A. M., & Alsamarai, M. A. (2021) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/1871523020666210920100707 · Cited by 48
ACE2 in chronic disease and COVID-19: gene regulation and post-translational modification
Wang, C., Chuang, H., & Tan, T. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00965-9 · Cited by 48
Cork, M. J., Thaçi, D., Eichenfield, L. F., Arkwright, P. D., Chen, Z., Thomas, R. B., Kosloski, M. P., Dubost-Brama, A., Prescilla, R. P., Bansal, A., et al. (2023) · Dermatology and Therapy · doi:10.1007/s13555-023-01016-9 · Cited by 49
Simpson, E. L. (2017) · Dermatology and Therapy · doi:10.1007/s13555-017-0181-6 · Cited by 45
Abbring, S., Wolf, J., Ayechu-Muruzabal, V., Diks, M. A. P., Alhamwe, B. A., Alhamdan, F., Harb, H., Renz, H. E., Garn, H., Garssen, J., et al. (2019) · Nutrients · doi:10.3390/nu11081721 · Cited by 46
Prins, L. D., Raap, U., Mueller, T., Schmid‐Grendelmeier, P., Haase, C. H., Backer, V., Fokkens, W. J., Benoist, L. B. L., Prokopakis, E. P., Doulaptsi, M., et al. (2022) · Frontiers in Allergy · doi:10.3389/falgy.2022.889221 · Cited by 49
Pelaia, C., Benfante, A., Busceti, M., Caiaffa, M., Campisi, R., Carpagnano, G., Crimi, N., D'Amato, M., Barbaro, M. F. F., Maglio, A., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1121237 · Cited by 39
Cheng, X., Wei, Y., Wang, R., Jia, C., Zhang, Z., An, J., Li, W., Zhang, J., & He, M. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102910 · Cited by 44
Immunologic Targets in Atopic Dermatitis and Emerging Therapies: An Update
Wang, D., & Beck, L. A. (2016) · American Journal of Clinical Dermatology · doi:10.1007/s40257-016-0205-5 · Cited by 48
Therapeutic targeting of the IL-13 pathway in skin inflammation
Tubau, C., & Puig, L. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1858802 · Cited by 50
Dou, T., Wang, J., Liu, Y., Jia, J., Zhou, L., Liu, G., Li, X., Han, M., Lin, J., Huang, F., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.800143 · Cited by 44
What has been learned by cytokine targeting of asthma?
Busse, W. W., & Viswanathan, R. K. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.06.010 · Cited by 44
The role of NLRP3 inflammasome in type 2 inflammation related diseases
Xu, S., Wang, D., Tan, L., & Lu, J. (2024) · Autoimmunity · doi:10.1080/08916934.2024.2310269 · Cited by 43
Strategies for Successful Management of Severe Atopic Dermatitis
Brar, K., Nicol, N. H., & Boguniewicz, M. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.10.021 · Cited by 44
Kiguchi, N., Sakaguchi, H., Kadowaki, Y., Saika, F., Fukazawa, Y., Matsuzaki, S., & Kishioka, S. (2016) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2016.11.005 · Cited by 46
Braile, M., Fiorelli, A., Sorriento, D., Crescenzo, R. M. D., Galdiero, M. R., Marone, G., Santini, M., Varricchi, G., & Loffredo, S. (2021) · Cells · doi:10.3390/cells10082012 · Cited by 42
Zhao, Y., Qi, C., Li, X., Lu, M., Zhang, H., Zhou, J., Dang, H., Chen, J., Li, S., Sun, J., et al. (2021) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202100699 · Cited by 41
The evolving algorithm of biological selection in severe asthma
Papadopoulos, N. G., Barnes, P. J., Canonica, G. W., Gaga, M., Heaney, L. G., Menzies-Gow, A. N., Kritikos, V. S., & Fitzgerald, M. (2020) · Allergy · doi:10.1111/all.14256 · Cited by 38
Targeting Interleukin 13 for the Treatment of Atopic Dermatitis
Lytvyn, Y., & Gooderham, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020568 · Cited by 42
Immunobiologicals in dermatology
da Silva, D. L. F., Secamilli, E. N., Beleli, M. V., Serrano, J. Y. M., França, A. F. E. D. C., & Magalhães, R. F. (2022) · Anais Brasileiros de Dermatologia · doi:10.1016/j.abd.2021.05.016 · Cited by 37
Siddiqui, S., Shikotra, A., Richardson, M., Doran, E., Choy, D. F., Bell, A. G., Austin, C. D., Eastham‐Anderson, J., Hargadon, B., Arron, J. R., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.12.982 · Cited by 38
Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis
Yang, N., Chen, Z., Zhang, X., & Shi, Y. (2021) · BioDrugs · doi:10.1007/s40259-021-00490-x · Cited by 39
Hoshino, M., Akitsu, K., Kubota, K., & Ohtawa, J. (2022) · Allergology International · doi:10.1016/j.alit.2022.05.010 · Cited by 38
Microglia M2A Polarization as Potential Link between Food Allergy and Autism Spectrum Disorders
Kalkman, H. O., & Feuerbach, D. (2017) · Pharmaceuticals · doi:10.3390/ph10040095 · Cited by 38
Advances and Highlights of miRNAs in Asthma: Biomarkers for Diagnosis and Treatment
Gil‐Martínez, M., Lorente‐Sorolla, C., Naharro, S., Rodrigo-Muñoz, J. M., & del Pozo, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021628 · Cited by 42
Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma
Zak, M., Dengler, H. S., & Rajapaksa, N. S. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126658 · Cited by 37
Treatments for Childhood Atopic Dermatitis: an Update on Emerging Therapies
Chu, C. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08799-1 · Cited by 37
Epigenetic Mechanisms in Allergy Development and Prevention
Potaczek, D. P., Alhamwe, B. A., Miethe, S., & Garn, H. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_475 · Cited by 38
Kwon, H. I., Jeong, N. H., Jun, S. H., Son, J. H., Kim, S., Jeon, H., Kang, S. C., Kim, S. H., & Lee, J. C. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.04.027 · Cited by 36
Wipperman, M. F., Gayvert, K. M., Atanasio, A., Wang, C. Q. F., Corren, J., Covarrubias, A., Setliff, I., Chio, E., Laws, E., Wolfe, K., et al. (2024) · Allergy · doi:10.1111/all.16001 · Cited by 37
Structure-Activity Relationships of Baicalein and its Analogs as Novel TSLP Inhibitors
Park, B. B., Choi, J. W., Park, D., Choi, D., Paek, J., Kim, H. J., Son, S.-Y., Mushtaq, A. U., Shin, H., Kim, S. H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-44853-5 · Cited by 35
Patient and physician preferences for atopic dermatitis injection treatments in Japan
Okubo, Y., Ho, K.-A., Fifer, S. J., Fujita, H., Oki, Y., & Taguchi, Y. (2019) · Journal of Dermatological Treatment · doi:10.1080/09546634.2019.1623860 · Cited by 35
Barrier Impairment and Type 2 Inflammation in Allergic Diseases: The Pediatric Perspective
Ghezzi, M., Pozzi, E., Abbattista, L., Lonoce, L., Zuccotti, G., & D’Auria, E. (2021) · Children · doi:10.3390/children8121165 · Cited by 39
Defining type 2 asthma and patients eligible for dupilumab in Italy: a biomarker-based analysis
Canonica, G. W., Blasi, F., Crimi, N., Paggiaro, P., Papi, A. A., Fanelli, F., Stassaldi, A., & Furneri, G. (2021) · Clinical and Molecular Allergy · doi:10.1186/s12948-021-00146-9 · Cited by 36
Hagino, T., Hamada, R., Yoshida, M., Fujimoto, E., Saeki, H., & Kanda, N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1365544 · Cited by 35
Zhang, Y., Yan, B., Zhu, Z., Wang, X., Song, X., Zhu, D., Ma, T., Zhang, Y., Meng, C., Wang, G., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102467 · Cited by 37
Chinese Position Paper on Biologic Therapy for Chronic Rhinosinusitis With Nasal Polyps
Xian, M., Yan, B., Song, X., Chen, J., Tang, J., Jiang, Y., Wan, L., Liu, W., Xue, J., Cao, Z., et al. (2025) · Allergy · doi:10.1111/all.16519 · Cited by 37
Price, D. B., Menzies-Gow, A. N., Bachert, C., Canonica, G. W., Kocks, J. W. H., Khan, A. H., Ye, F., Rowe, P. J., Lü, Y., Kamat, S., et al. (2021) · Journal of Asthma and Allergy · doi:10.2147/jaa.s321212 · Cited by 35
Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma
Dengler, H. S., Wu, X., Peng, I., Rinderknecht, C. H., Kwon, Y. C., Suto, E., Kohli, P. B., Liimatta, M. B., Barrett, K., Lloyd, J., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao2151 · Cited by 33
Maurer, M., Casale, T. B., Saini, S. S., Ben‐Shoshan, M., Laws, E., Maloney, J. M., Bauer, D., Radin, A. R., & Makhija, M. (2024) · Dermatology and Therapy · doi:10.1007/s13555-024-01231-y · Cited by 37
Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2024
Saeki, H., Ohya, Y., Arakawa, H., Ichiyama, S., Katsunuma, T., Katoh, N., Tanaka, A., Tanizaki, H., Tsunemi, Y., Nakahara, T., et al. (2025) · Allergology International · doi:10.1016/j.alit.2025.01.003 · Cited by 37
Engineering of anti-human interleukin-4 receptor alpha antibodies with potent antagonistic activity
Kim, J.-E., Jung, K., Kim, J.-A., Kim, S., Park, H., & Kim, Y. (2019) · Scientific Reports · doi:10.1038/s41598-019-44253-9 · Cited by 32
Huang, Q., Han, L., Lv, R., & Ling, L. (2019) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2019.23.4.251 · Cited by 33
Miniotti, M., Lazzarin, G., Ortoncelli, M., Mastorino, L., Ribero, S., & Leombruni, P. (2022) · Dermatologic Therapy · doi:10.1111/dth.15407 · Cited by 34
Peters, A. T., Wagenmann, M., Bernstein, J. A., Khan, A. H., Nash, S., Jacob-Nara, J. A., Siddiqui, S. S., Rowe, P. J., & Deniz, Y. M. (2023) · Allergy and Asthma Proceedings · doi:10.2500/aap.2023.44.230015 · Cited by 35
Initiation of inflammatory tumorigenesis by CTLA4 insufficiency due to type 2 cytokines
Miska, J. M., Lui, J. B., Toomer, K. H., Devarajan, P., Cai, X., Houghton, J., Lopez, D. M., Abreu, M. T., Wang, G., & Chen, Z. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171971 · Cited by 34
Dupilumab for Atopic Dermatitis: The Silver Bullet We Have Been Searching for?
Tameez‐ud‐din, A., Malik, I. J., Arshad, D., & Din, A. T. U. (2020) · Cureus · doi:10.7759/cureus.7565 · Cited by 37
de Bruin-Weller, M. S., Pink, A., Patrizi, A., Giménez‐Arnau, A. M., Agner, T., Roquet-Gravy, P.-P., Ferrucci, S. M., Arenberger, P., Svensson, Å., Schuttelaar, M. L. A., et al. (2021) · Journal of Dermatological Treatment · doi:10.1080/09546634.2020.1866741 · Cited by 32
Chen, W., Cao, Y., Zhong, Y., Sun, J., & Dong, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.862866 · Cited by 36
Th2A cells: The pathogenic players in allergic diseases
Huang, Z., Chu, M., Chen, X., Wang, Z., Lin, J., Ma, Y., & Wang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.916778 · Cited by 31
Yan, S., Wu, X., Jiang, J., Yu, S., Fang, X., Yang, H., Bai, X., Wang, H., & Luo, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1054422 · Cited by 31
Kołkowski, K., Trzeciak, M., & Sokołowska-Wojdyło, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413388 · Cited by 30
Aeroallergens in atopic dermatitis and chronic urticaria
Chong, A. C., Chwa, W. J., & Ong, P. Y. (2022) · Current Allergy and Asthma Reports · doi:10.1007/s11882-022-01033-2 · Cited by 30
Griffiths, C. E. M., de Bruin-Weller, M. S., Deleuran, M. S., Fargnoli, M. C., Staumont-Sallé, D., Hong, C.-H., Sánchez‐Carazo, J. L., Foley, P. A., Seo, S. J., Msihid, J., et al. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00558-0 · Cited by 30
Rabe, K. F., FitzGerald, J. M., Bateman, E. D., Castro, M., Pavord, I. D., Maspero, J. F., Busse, W. W., Izuhara, K., Daizadeh, N. S., Ortiz, B. D., et al. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.06.036 · Cited by 32
Cai, S., Chen, Y., Hu, Z., Zhou, T., Huang, Y., Lin, S., Gao, R., Zhong, J., & Dong, L. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102944 · Cited by 33
Metadata
- Authors
- Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N., & Yancopoulos, G. D.
- Affiliations
- Regeneron (United States) (US)
- Sanofi (United States) (US)
- Corresponding author
- Gandhi, Namita A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-10-16
- Volume
- 15
- Issue
- 1
- Pages
- 35-50
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2200308911
- Cited by
- 766
- References
- 156
- Citations by year
- 2026: 70 · 2025: 104 · 2024: 113 · 2023: 77 · 2022: 106 · 2021: 99 · 2020: 63 · 2019: 43 · 2018: 33 · 2017: 38 · 2016: 18
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Keywords
- type 2 inflammation, IL-4, IL-5, IL-13, asthma, atopic dermatitis, Th2 cells, allergic diseases, IL-4 receptor alpha inhibition, IL-13 inhibition, IL-5 inhibition, personalized asthma therapy, drug candidates
- MeSH terms
- Antibodies, Monoclonal, T-Lymphocytes, Helper-Inducer, Humans, Inflammation, Interleukin-4, Interleukin-5, Models, Immunological, Interleukin-13, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.